Bolt Biotherapeutics, Inc.
BOLT
NASDAQ·Healthcare·Biotechnology·Mkt cap $6.6M
$3.51
▼ -4.62%
P/E
—
Mkt Cap
$6.6M
52-Wk Range
$3.10–$7.20
52-Week Range
$3.10 - $7.20
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 34.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary immuno-oncology platform targeting tumor microenvironment
- Novel mechanisms of action addressing checkpoint inhibitor resistance
- Strong clinical-stage pipeline with multiple programs in development
- Expertise in HER2-low tumor segment with limited therapeutic options
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Clinical trial progression and regulatory approvals of lead candidates
Value
Valuation data unavailable
Momentum
Weak
-14.0% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying BOLT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 11, 2026
Reported EPS of -$4.57 vs -$3.39 consensus (-34.8% surprise). Revenue of $5.0K vs $500.0K expected (-99.0%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-34.8%
Revenue trend · last 8Q
—
—
-77%
+41%
+90%
—
-98%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$1.1M
$0
$1.2M
$1.8M
$2.2M
$2.5M
$26.0K
$5.0K
Margins · last 8Q
Gross
0.0%
Profit
-154400.0%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · May 28, 2026
vs Industry
How BOLT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related